Answers are grounded in this paper and cite their sources.
Narrative review outlines distinct pulmonary toxicity profiles from therapies in inflammatory bowel disease, highlighting the need for prompt diagnosis and targeted management.
Background: Increasing use of immunomodulators and biologics in IBD has expanded the spectrum of pulmonary complications. Objective: To summarize mechanisms, clinical features, and management of druginduced pulmonary toxicity in IBD. Methods: Narrative review of relevant studies from major databases. Results: Each drug class exhibits a characteristic pulmonary toxicity profile, requiring distinct diagnostic and therapeutic approaches. Conclusions: Clinicians must maintain high suspicion for pulmonary toxicity to ensure timely intervention and improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Alsadik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: